ARF-BP1 as a potential therapeutic target

In this review, we discuss the recent identification of ARF-BP1 (also known as Mule, UREB1, E3(histone), LASU1, and HectH9). ARF-BP1, a HECT domain-containing E3 ubiquitin ligase, interacts with ARF and p53. Its ubiquitin ligase activity is inhibited by ARF. Inactivation of ARF-BP1 stabilised p53 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, D, Brooks, C L, Gu, W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361317/
https://www.ncbi.nlm.nih.gov/pubmed/16641901
http://dx.doi.org/10.1038/sj.bjc.6603119
_version_ 1782153186617851904
author Chen, D
Brooks, C L
Gu, W
author_facet Chen, D
Brooks, C L
Gu, W
author_sort Chen, D
collection PubMed
description In this review, we discuss the recent identification of ARF-BP1 (also known as Mule, UREB1, E3(histone), LASU1, and HectH9). ARF-BP1, a HECT domain-containing E3 ubiquitin ligase, interacts with ARF and p53. Its ubiquitin ligase activity is inhibited by ARF. Inactivation of ARF-BP1 stabilised p53 and induced apoptosis. Notably, inactivation of ARF-BP1 also caused cell growth repression in p53-null cells and breast cancer cells with mutant p53. Thus, ARF-BP1 emerges as a novel therapeutic target against cancer regardless of p53 status.
format Text
id pubmed-2361317
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23613172009-09-10 ARF-BP1 as a potential therapeutic target Chen, D Brooks, C L Gu, W Br J Cancer Minireview In this review, we discuss the recent identification of ARF-BP1 (also known as Mule, UREB1, E3(histone), LASU1, and HectH9). ARF-BP1, a HECT domain-containing E3 ubiquitin ligase, interacts with ARF and p53. Its ubiquitin ligase activity is inhibited by ARF. Inactivation of ARF-BP1 stabilised p53 and induced apoptosis. Notably, inactivation of ARF-BP1 also caused cell growth repression in p53-null cells and breast cancer cells with mutant p53. Thus, ARF-BP1 emerges as a novel therapeutic target against cancer regardless of p53 status. Nature Publishing Group 2006-06-05 2006-04-25 /pmc/articles/PMC2361317/ /pubmed/16641901 http://dx.doi.org/10.1038/sj.bjc.6603119 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Minireview
Chen, D
Brooks, C L
Gu, W
ARF-BP1 as a potential therapeutic target
title ARF-BP1 as a potential therapeutic target
title_full ARF-BP1 as a potential therapeutic target
title_fullStr ARF-BP1 as a potential therapeutic target
title_full_unstemmed ARF-BP1 as a potential therapeutic target
title_short ARF-BP1 as a potential therapeutic target
title_sort arf-bp1 as a potential therapeutic target
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361317/
https://www.ncbi.nlm.nih.gov/pubmed/16641901
http://dx.doi.org/10.1038/sj.bjc.6603119
work_keys_str_mv AT chend arfbp1asapotentialtherapeutictarget
AT brookscl arfbp1asapotentialtherapeutictarget
AT guw arfbp1asapotentialtherapeutictarget

Ejemplares similares